Metabolic Solutions’ improves on TZD safety
This article was originally published in Pharmaceutical Approvals Monthly
Metabolic Solutions Development Company reports preliminary Phase IIa data showing its lead compound, MSDC-0160, improves insulin sensitivity and lowers blood glucose levels in humans without the side effects of current therapies when taken over a 28-day period. The firm says MSDC-0160, a PPAR-sparing thiazolidinedione (TZD) is similar to Lilly's TZD Actos (pioglitazone) in that it lowers circulation of fatty acids and increases HDL cholesterol, but dissimilar from Actos in that is does not decrease the levels of circulating blood cells or cause weight gain. Delivering a similar drug that would avoid the safety concerns with the broad TZDs, including the cardiovascular safety issues with GSK's Avandia (rosiglitazone), could be a significant market opportunity. The company will gather additional safety and expanded efficacy data in a 90-day Phase IIb study planned for late 2009. The firm also plans to submit an IND for a second-generation compound by the end of 2009. MSDC President Jerry Colca participated in the early development of pioglitazone while working at Upjohn
You may also be interested in...
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.